All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ropinirole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	2402	91374-21-9

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: ropinirol requip ropinirole ropinirole hydrochloride ropinirole HCl

Ropinirole is a non-ergoline dopamine agonist. The precise mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, although it is thought to be related to its ability to stimulate dopamine D2 receptors within the caudate-putamen in the brain. Molecular weight: 260.38 Formula: C16H24N2O CLOGP: 2.80 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 32.34 ALOGS: -2.87 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
6	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	133 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.32 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	55 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	7.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.60 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.970		Moderate	0.78
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.222		Moderate	0.78
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	19.907	10^-6 cm/s	Moderate	0.78
dh-clint	Dog hepatocyte intrinsic clearance	4.853	uL/min/10^6 cells	Moderate	0.78
dppb	Dog plasma protein binding (% unbound)	81.740	%	Moderate	0.78
fcs-ppb	Fetal calf serum protein binding (% unbound)	81.360	%	Moderate	0.78
herg	hERG pIC50	4.953	pIC50	Moderate	0.78
hh-clint	Human hepatocyte intrinsic clearance	2.455	uL/min/10^6 cells	Moderate	0.78
hlm-clint	Human liver microsomal intrinsic clearance	16.866	uL/min/mg protein	Moderate	0.78
hppb	Human plasma protein binding (% unbound)	74.030	%	Moderate	0.78
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1	36
kinase-selectivity-class	AXL,CAMK2D,CDK4,EIF2AK3,GRK2,MAP2K6,MAPK7,PDK4,SIK2,STK33,TEK,TTK	12
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.133		Moderate	0.78
mh-clint	Mouse hepatocyte intrinsic clearance	69.663		Moderate	0.78
mppb	Mouse plasma protein binding (% unbound)	80.440		Moderate	0.78
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	6.310		Moderate	0.78
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	1		High	1
pppb	Pig plasma protein binding (% unbound)	84.030	%	Moderate	0.78
rh-clint	Rat hepatocyte intrinsic clearance	146.218	uL/min/10^6 cells	Moderate	0.78
rh-fuinc	Rat hepatocyte fraction unbound in incubation	91.120	%	Moderate	0.78
rppb	Rat plasma protein binding (% unbound)	79.060	%	Moderate	0.78
solubility-dd	Solubility at pH 7.4 in DMSO	866.962	uM	Moderate	0.78

Approvals:

Date	Agency	Company	Orphan
Sept. 20, 2019	PMDA	Hisamitsu Pharmaceutical Co., Inc.
Sept. 19, 1997	FDA	GLAXOSMITHKLINE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	338.43	13.95	184	28303	36350	90563610
On and off phenomenon	307.92	13.95	84	28403	2459	90597501
Compulsive shopping	200.98	13.95	47	28440	722	90599238
Hallucination	192.14	13.95	162	28325	65797	90534163
Hallucination, visual	161.88	13.95	97	28390	22995	90576965
Dopamine dysregulation syndrome	157.29	13.95	30	28457	156	90599804
Restless legs syndrome	153.92	13.95	93	28394	22377	90577583
Full blood count abnormal	130.06	13.95	101	28386	36496	90563464
Fall	128.51	13.95	387	28100	481423	90118537
Tremor	124.88	13.95	194	28293	152979	90446981
Stoma site discharge	122.85	13.95	39	28448	1950	90598010
Freezing phenomenon	118.02	13.95	37	28450	1775	90598185
Impulse-control disorder	107.63	13.95	30	28457	952	90599008
Stoma site erythema	91.02	13.95	29	28458	1467	90598493
Hyperglycaemia	90.23	13.95	95	28392	50875	90549085
Bradykinesia	88.31	13.95	43	28444	6745	90593215
Gait disturbance	87.75	13.95	228	28259	260268	90339692
Hyperkinesia	83.93	13.95	29	28458	1890	90598070
Gambling	78.78	13.95	18	28469	248	90599712
Systemic lupus erythematosus	77.24	13.95	11	28476	361885	90238075
Glossodynia	75.61	13.95	7	28480	321772	90278188
Contraindicated product administered	75.12	13.95	7	28480	320132	90279828
Infusion related reaction	69.96	13.95	22	28465	416758	90183202
Parkinsonism hyperpyrexia syndrome	69.66	13.95	16	28471	226	90599734
Product dose omission issue	66.30	13.95	222	28265	291465	90308495
Treatment failure	63.09	13.95	10	28477	303918	90296042
Gambling disorder	62.92	13.95	21	28466	1231	90598729
Hepatic enzyme increased	62.42	13.95	18	28469	360718	90239242
Joint swelling	59.42	13.95	43	28444	503257	90096703
Muscle rigidity	58.60	13.95	43	28444	14266	90585694
Gastrooesophageal reflux disease	58.44	13.95	148	28339	166189	90433771
Delusion	57.61	13.95	42	28445	13798	90586162
Asthma	56.52	13.95	186	28301	241974	90357986
Feeling abnormal	54.84	13.95	145	28342	167090	90432870
Jealous delusion	50.80	13.95	10	28477	63	90599897
Exposure during pregnancy	49.12	13.95	8	28479	238402	90361558
Balance disorder	46.94	13.95	98	28389	96982	90502978
Parkinsonian gait	46.68	13.95	14	28473	578	90599382
Lower respiratory tract infection	44.29	13.95	12	28475	250647	90349313
Muscle injury	43.82	13.95	3	28484	176651	90423309
Withdrawal syndrome	43.49	13.95	44	28443	22480	90577480
Stomatitis	43.46	13.95	16	28471	274682	90325278
Wound	42.58	13.95	21	28466	302959	90297001
Arthropathy	42.27	13.95	32	28455	366210	90233750
Impaired healing	41.77	13.95	11	28476	234188	90365772
Stoma site pain	41.75	13.95	16	28471	1401	90598559
Acute psychosis	41.55	13.95	20	28467	3058	90596902
Posture abnormal	40.84	13.95	19	28468	2692	90597268
Illusion	39.87	13.95	15	28472	1249	90598711
Abnormal dreams	39.83	13.95	31	28456	11226	90588734
Irritable bowel syndrome	38.44	13.95	9	28478	207439	90392521
Dystonia	38.36	13.95	36	28451	16783	90583177
Drug intolerance	38.08	13.95	51	28436	447540	90152420
Hypersexuality	37.53	13.95	12	28475	614	90599346
Multiple sclerosis relapse	36.77	13.95	62	28425	52243	90547717
Behaviour disorder	36.50	13.95	21	28466	4614	90595346
Ill-defined disorder	36.35	13.95	7	28480	184884	90415076
Drug withdrawal syndrome	36.33	13.95	45	28442	28678	90571282
Stoma site reaction	35.94	13.95	10	28477	315	90599645
Depression	34.61	13.95	186	28301	300415	90299545
Insomnia	34.19	13.95	200	28287	333274	90266686
Alopecia	34.02	13.95	65	28422	495006	90104954
Binge eating	33.83	13.95	11	28476	594	90599366
Tension	32.56	13.95	18	28469	3664	90596296
Urinary tract infection	31.78	13.95	184	28303	305448	90294512
Discomfort	31.60	13.95	24	28463	274311	90325649
Psychotic symptom	31.49	13.95	15	28472	2241	90597719
Blood cholesterol increased	31.43	13.95	13	28474	207999	90391961
Polyp	31.37	13.95	23	28464	7621	90592339
Muscle spasms	31.15	13.95	159	28328	251724	90348236
Somnolence	30.93	13.95	139	28348	208945	90391015
Memory impairment	30.60	13.95	133	28354	197111	90402849
Rapid eye movement sleep behaviour disorder	29.90	13.95	9	28478	376	90599584
Oromandibular dystonia	29.85	13.95	10	28477	593	90599367
Multiple sclerosis	29.56	13.95	40	28447	27800	90572160
Pyrexia	29.20	13.95	108	28379	660377	89939583
Catecholamines urine increased	28.93	13.95	5	28482	13	90599947
Off label use	27.76	13.95	218	28269	1102034	89497926
Limbic encephalitis	27.75	13.95	8	28479	287	90599673
Death	27.61	13.95	241	28246	456310	90143650
Mental impairment	27.52	13.95	30	28457	16690	90583270
Rheumatoid arthritis	26.32	13.95	46	28441	362568	90237392
Parkinsonism	26.29	13.95	27	28460	14038	90585922
Anxiety	26.26	13.95	177	28310	309595	90290365
Blister	26.08	13.95	25	28462	254973	90344987
Therapy interrupted	25.88	13.95	52	28435	50056	90549904
Bursitis	25.84	13.95	5	28482	131649	90468311
Injury	25.78	13.95	15	28472	197334	90402626
Impulsive behaviour	25.68	13.95	12	28475	1718	90598242
Stoma site infection	25.54	13.95	10	28477	928	90599032
Pleurothotonus	25.35	13.95	11	28476	1324	90598636
Dizziness	24.53	13.95	288	28199	588996	90010964
Stereotypy	24.32	13.95	8	28479	448	90599512
Tardive dyskinesia	24.17	13.95	23	28464	10907	90589053
Device issue	23.45	13.95	37	28450	29500	90570460
Wound infection	23.23	13.95	3	28484	106399	90493561
Nasal congestion	23.06	13.95	68	28419	83346	90516614
Therapeutic response unexpected	22.57	13.95	31	28456	21849	90578111
Abdominal discomfort	22.44	13.95	76	28411	477252	90122708
Febrile neutropenia	22.19	13.95	11	28476	158338	90441622
Stoma site irritation	22.10	13.95	7	28480	347	90599613
Gastrointestinal disorder	22.06	13.95	29	28458	256658	90343302
Eczema eyelids	22.03	13.95	7	28480	351	90599609
Speech disorder	22	13.95	46	28441	45539	90554421
Haemorrhoids	21.97	13.95	34	28453	26668	90573292
Extra dose administered	21.73	13.95	20	28467	9098	90590862
Fibroma	21.72	13.95	9	28478	967	90598993
Inflammation	21.37	13.95	15	28472	178577	90421383
Reduced facial expression	21.26	13.95	12	28475	2541	90597419
Completed suicide	21.12	13.95	96	28391	144962	90454998
Irritability	20.85	13.95	39	28448	35623	90564337
Therapeutic product effect variable	20.77	13.95	10	28477	1529	90598431
Occipital neuralgia	20.75	13.95	8	28479	712	90599248
Psoriatic arthropathy	20.45	13.95	25	28462	228310	90371650
Serotonin syndrome	20.39	13.95	40	28447	37847	90562113
Chronic obstructive pulmonary disease	20.23	13.95	60	28427	73769	90526191
Major depression	20.10	13.95	20	28467	10015	90589945
General physical health deterioration	19.96	13.95	52	28435	355063	90244897
Spinal operation	19.83	13.95	20	28467	10176	90589784
Dropped head syndrome	19.75	13.95	6	28481	259	90599701
Pre-existing condition improved	19.72	13.95	19	28468	9150	90590810
Weight decreased	19.65	13.95	194	28293	379716	90220244
Akinesia	19.63	13.95	10	28477	1726	90598234
Device occlusion	19.52	13.95	19	28468	9263	90590697
Liver disorder	19.27	13.95	7	28480	121262	90478698
Resting tremor	19.17	13.95	8	28479	875	90599085
Surgery	19.04	13.95	43	28444	44844	90555116
Secondary hypertension	18.95	13.95	6	28481	297	90599663
Abnormal behaviour	18.88	13.95	29	28458	22599	90577361
Hypertension	18.79	13.95	77	28410	457455	90142505
Stoma site extravasation	18.74	13.95	6	28481	308	90599652
Sudden onset of sleep	18.66	13.95	7	28480	578	90599382
Therapeutic response shortened	18.64	13.95	29	28458	22850	90577110
Movement disorder	18.57	13.95	33	28454	28986	90570974
Back pain	18.41	13.95	166	28321	317009	90282951
Periodic limb movement disorder	18.38	13.95	7	28480	603	90599357
Somatic delusion	18.33	13.95	7	28480	607	90599353
Hyperhidrosis	18.22	13.95	88	28399	136217	90463743
Teeth brittle	18.05	13.95	7	28480	633	90599327
Logorrhoea	17.93	13.95	11	28476	2716	90597244
Infusion site abscess	17.70	13.95	6	28481	369	90599591
Living in residential institution	17.66	13.95	7	28480	671	90599289
Initial insomnia	17.63	13.95	18	28469	9292	90590668
Blood catecholamines increased	17.58	13.95	4	28483	54	90599906
Vision blurred	17.57	13.95	75	28412	110218	90489742
Thrombocytopenia	17.50	13.95	24	28463	208701	90391259
Crying	17.49	13.95	30	28457	25615	90574345
Pulmonary fibrosis	17.43	13.95	6	28481	107497	90492463
Obsessive-compulsive disorder	17.24	13.95	13	28474	4491	90595469
Poor quality sleep	16.99	13.95	29	28458	24664	90575296
Apathy	16.78	13.95	19	28468	11021	90588939
Dermatitis contact	16.71	13.95	21	28466	13574	90586386
Vitamin B6 deficiency	16.70	13.95	5	28482	205	90599755
Red blood cell sedimentation rate increased	16.50	13.95	3	28484	82592	90517368
Labelled drug-disease interaction issue	16.35	13.95	4	28483	75	90599885
Primary myelofibrosis	16.25	13.95	4	28483	77	90599883
Swelling	15.70	13.95	73	28414	418985	90180975
Cornea verticillata	15.69	13.95	5	28482	253	90599707
Wheezing	15.68	13.95	32	28455	238048	90361912
Illness	15.67	13.95	59	28428	81910	90518050
Nightmare	15.60	13.95	26	28461	21699	90578261
Unevaluable event	15.43	13.95	45	28442	54803	90545157
Camptocormia	15.06	13.95	5	28482	288	90599672
Product administration interrupted	14.89	13.95	19	28468	12473	90587487
Coma scale abnormal	14.70	13.95	13	28474	5613	90594347
Acquired haemophilia	14.59	13.95	7	28480	1062	90598898
Basophil percentage increased	14.47	13.95	4	28483	123	90599837
Clavicle fracture	14.32	13.95	11	28476	3905	90596055
Sleep attacks	14.32	13.95	4	28483	128	90599832
Energy increased	14.17	13.95	10	28477	3120	90596840
Dreamy state	14.01	13.95	3	28484	30	90599930

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	412.72	15.31	260	15586	57247	42548242
Hypersexuality	317.72	15.31	82	15764	1620	42603869
Impulse-control disorder	299.45	15.31	77	15769	1498	42603991
Dyskinesia	277.70	15.31	151	15695	25239	42580250
On and off phenomenon	243.50	15.31	78	15768	3389	42602100
Freezing phenomenon	221.11	15.31	63	15783	1826	42603663
Gambling disorder	211.34	15.31	60	15786	1716	42603773
Hallucination, visual	205.10	15.31	116	15730	20904	42584585
Dopamine dysregulation syndrome	180.20	15.31	42	15804	531	42604958
Muscle rigidity	132.52	15.31	72	15774	11987	42593502
Sudden onset of sleep	113.35	15.31	27	15819	377	42605112
Jealous delusion	112.76	15.31	27	15819	386	42605103
Stoma site discharge	106.88	15.31	34	15812	1442	42604047
Fall	98.20	15.31	247	15599	234273	42371216
Bradykinesia	93.62	15.31	44	15802	5392	42600097
Somnolence	89.98	15.31	176	15670	140929	42464560
Compulsive shopping	89.87	15.31	23	15823	438	42605051
Stoma site erythema	88.83	15.31	27	15819	983	42604506
Restless legs syndrome	70.08	15.31	44	15802	9570	42595919
Hyperkinesia	69.50	15.31	27	15819	2071	42603418
Device dislocation	65.15	15.31	39	15807	7792	42597697
Delusion	61.72	15.31	48	15798	14686	42590803
Aggression	61.65	15.31	79	15767	44084	42561405
Psychotic disorder	58.71	15.31	63	15783	29145	42576344
Confusional state	56.38	15.31	163	15683	167434	42438055
Serotonin syndrome	55.95	15.31	58	15788	25787	42579702
Abnormal dreams	55.68	15.31	36	15810	8235	42597254
Libido increased	52.61	15.31	18	15828	960	42604529
Stereotypy	51.23	15.31	17	15829	825	42604664
Balance disorder	51.05	15.31	75	15771	47570	42557919
Stoma site reaction	48.10	15.31	13	15833	308	42605181
Compulsions	46.62	15.31	12	15834	234	42605255
Dropped head syndrome	46.14	15.31	12	15834	244	42605245
Paraphilia	45.99	15.31	10	15836	90	42605399
Fibroma	44.80	15.31	13	15833	402	42605087
Orthostatic hypotension	44.74	15.31	56	15790	30514	42574975
Tremor	43.48	15.31	105	15741	96824	42508665
Gambling	43.41	15.31	11	15835	201	42605288
Mobility decreased	42.87	15.31	59	15787	35247	42570242
Febrile neutropenia	41.82	15.31	9	15837	185694	42419795
Memory impairment	41.26	15.31	70	15776	50152	42555337
Abnormal behaviour	41.19	15.31	50	15796	26401	42579088
Therapeutic product effect variable	41.06	15.31	21	15825	3088	42602401
Insomnia	40.67	15.31	116	15730	118137	42487352
Compulsive sexual behaviour	40.41	15.31	11	15835	268	42605221
Stoma site pain	40.18	15.31	14	15832	789	42604700
Gait disturbance	38.55	15.31	101	15745	97899	42507590
Tension	36.53	15.31	18	15828	2446	42603043
Behaviour disorder	36.28	15.31	26	15820	7028	42598461
Hypersomnia	35.65	15.31	35	15811	14583	42590906
Mania	34.99	15.31	30	15816	10517	42594972
Reduced facial expression	34.63	15.31	15	15831	1518	42603971
Alien limb syndrome	34.49	15.31	5	15841	0	42605489
Stoma site inflammation	33.36	15.31	11	15835	523	42604966
Disturbance in attention	31.96	15.31	47	15799	29819	42575670
Sleep attacks	31.84	15.31	8	15838	141	42605348
Speech disorder	31.41	15.31	46	15800	29075	42576414
Cognitive disorder	31.25	15.31	50	15796	34122	42571367
Irritability	31.17	15.31	45	15801	28083	42577406
Impulsive behaviour	30.93	15.31	16	15830	2409	42603080
Agitation	30.25	15.31	71	15775	64243	42541246
Middle insomnia	29.55	15.31	24	15822	7809	42597680
Parkinsonism hyperpyrexia syndrome	29.04	15.31	9	15837	350	42605139
Excessive sexual fantasies	28.37	15.31	5	15841	12	42605477
Anticholinergic syndrome	27.78	15.31	13	15833	1576	42603913
Nonspecific reaction	27.69	15.31	13	15833	1588	42603901
Drug withdrawal syndrome	27.65	15.31	37	15809	21512	42583977
Stoma site hypergranulation	27.46	15.31	8	15838	251	42605238
Embedded device	27.20	15.31	9	15837	433	42605056
Dystonia	26.42	15.31	28	15818	12762	42592727
Obsessive-compulsive disorder	26.15	15.31	21	15825	6722	42598767
Stress cardiomyopathy	26.14	15.31	15	15831	2770	42602719
Multiple organ dysfunction syndrome	25.65	15.31	3	15843	97032	42508457
Tic	25.53	15.31	14	15832	2369	42603120
Neutropenia	24.31	15.31	23	15823	199408	42406081
Urinary tract infection	23.73	15.31	86	15760	99198	42506291
Incorrect product dosage form administered	23.57	15.31	7	15839	235	42605254
Transvestism	23.20	15.31	4	15842	8	42605481
Paranoia	22.63	15.31	27	15819	13999	42591490
Progressive supranuclear palsy	22.52	15.31	5	15841	50	42605439
Diarrhoea	22.33	15.31	92	15754	460757	42144732
Gait inability	21.69	15.31	34	15812	22799	42582690
Medical device discomfort	21.69	15.31	5	15841	60	42605429
Thunderclap headache	21.67	15.31	6	15840	156	42605333
Exhibitionism	21.61	15.31	5	15841	61	42605428
Pyrexia	21.45	15.31	75	15771	393967	42211522
Parkinsonian rest tremor	21.41	15.31	7	15839	324	42605165
Generalised onset non-motor seizure	21.16	15.31	4	15842	16	42605473
Hypokinesia	21.08	15.31	22	15824	9849	42595640
Sexually inappropriate behaviour	20.57	15.31	8	15838	615	42604874
Torsade de pointes	19.89	15.31	20	15826	8574	42596915
Akinesia	19.76	15.31	12	15834	2460	42603029
Suspiciousness	19.63	15.31	7	15839	422	42605067
Hypomania	19.60	15.31	12	15834	2496	42602993
Theft	19.32	15.31	6	15840	235	42605254
Bipolar disorder	19.13	15.31	14	15832	3908	42601581
Stoma site haemorrhage	19.09	15.31	9	15837	1110	42604379
Nocturia	19.02	15.31	23	15823	12089	42593400
Rehabilitation therapy	19.00	15.31	9	15837	1121	42604368
Acute kidney injury	18.61	15.31	72	15774	367265	42238224
Salivary gland cancer stage IV	18.50	15.31	4	15842	35	42605454
Device kink	18.45	15.31	7	15839	503	42604986
Excessive masturbation	18.25	15.31	5	15841	125	42605364
Dysphagia	18.23	15.31	64	15782	72655	42532834
Oedema peripheral	18.13	15.31	99	15747	135977	42469512
Product dispensing error	18.09	15.31	18	15828	7621	42597868
Restlessness	17.99	15.31	36	15810	29213	42576276
Mydriasis	17.76	15.31	19	15827	8751	42596738
Psychomotor hyperactivity	17.52	15.31	21	15825	10937	42594552
Micturition disorder	17.20	15.31	11	15835	2469	42603020
Poor quality sleep	16.61	15.31	19	15827	9421	42596068
Toxicity to various agents	16.58	15.31	38	15808	229098	42376391
Neuroleptic malignant syndrome	16.41	15.31	29	15817	21443	42584046
Malignant neoplasm progression	16.39	15.31	10	15836	108390	42497099
Dementia	16.29	15.31	25	15821	16455	42589034
Suicidal ideation	16.29	15.31	47	15799	48114	42557375
Homosexuality	16.28	15.31	4	15842	64	42605425
Hallucinations, mixed	16.17	15.31	12	15834	3423	42602066
Logorrhoea	15.95	15.31	11	15835	2796	42602693
Hyperphagia	15.69	15.31	9	15837	1661	42603828
Dizziness	15.50	15.31	151	15695	249103	42356386

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	464.02	12.72	256	35095	51190	110502758
Hallucination	460.06	12.72	326	35025	101106	110452842
On and off phenomenon	405.66	12.72	118	35233	4306	110549642
Hallucination, visual	356.86	12.72	197	35154	39408	110514540
Impulse-control disorder	342.88	12.72	89	35262	2105	110551843
Dopamine dysregulation syndrome	340.18	12.72	70	35281	557	110553391
Freezing phenomenon	254.36	12.72	73	35278	2536	110551412
Hypersexuality	238.07	12.72	65	35286	1875	110552073
Gambling disorder	216.72	12.72	62	35289	2129	110551819
Compulsive shopping	215.22	12.72	51	35300	817	110553131
Fall	197.13	12.72	527	34824	602955	109950993
Jealous delusion	166.67	12.72	37	35314	436	110553512
Stoma site discharge	152.16	12.72	50	35301	2745	110551203
Restless legs syndrome	149.58	12.72	95	35256	24531	110529417
Bradykinesia	135.28	12.72	67	35284	10721	110543227
Hyperkinesia	130.35	12.72	46	35305	3138	110550810
Muscle rigidity	122.30	12.72	83	35268	23948	110530000
Stoma site erythema	115.76	12.72	38	35313	2079	110551869
Tremor	115.66	12.72	221	35130	202011	110351937
Delusion	104.42	12.72	75	35276	23680	110530268
Gait disturbance	104.00	12.72	256	35095	277952	110275996
Parkinsonism hyperpyrexia syndrome	96.22	12.72	25	35326	593	110553355
Full blood count abnormal	93.42	12.72	102	35249	55950	110497998
Somnolence	93.00	12.72	256	35095	297193	110256755
Gambling	92.97	12.72	22	35329	350	110553598
Behaviour disorder	81.42	12.72	46	35305	9601	110544347
Sudden onset of sleep	78.92	12.72	22	35329	686	110553262
Serotonin syndrome	75.73	12.72	94	35257	59059	110494889
Dystonia	71.35	12.72	62	35289	25743	110528205
Stereotypy	66.86	12.72	21	35330	996	110552952
Drug withdrawal syndrome	64.71	12.72	70	35281	37984	110515964
Aggression	63.17	12.72	86	35265	59124	110494824
Irritability	61.24	12.72	76	35275	47733	110506215
Balance disorder	60.07	12.72	122	35229	116438	110437510
Treatment failure	56.89	12.72	10	35341	277224	110276724
Psychotic disorder	55.89	12.72	75	35276	50862	110503086
Contraindicated product administered	55.44	12.72	7	35344	248260	110305688
Abnormal dreams	55.36	12.72	40	35311	12740	110541208
Hepatic enzyme increased	55.12	12.72	17	35334	320875	110233073
Impulsive behaviour	55.09	12.72	25	35326	3290	110550658
Systemic lupus erythematosus	54.83	12.72	8	35343	254330	110299618
Hand deformity	54.47	12.72	4	35347	218502	110335446
Withdrawal syndrome	53.84	12.72	58	35293	31322	110522626
Hyperglycaemia	53.60	12.72	97	35254	84993	110468955
Therapeutic product effect variable	53.23	12.72	23	35328	2695	110551253
Feeling abnormal	51.98	12.72	151	35200	180560	110373388
Dropped head syndrome	51.93	12.72	15	35336	533	110553415
Acute psychosis	51	12.72	27	35324	4960	110548988
Febrile neutropenia	48.91	12.72	20	35331	316747	110237201
Glossodynia	47.81	12.72	7	35344	221997	110331951
Helicobacter infection	46.29	12.72	3	35348	181874	110372074
Infusion related reaction	45.85	12.72	33	35318	381129	110172819
Product dose omission issue	45.08	12.72	213	35138	321569	110232379
Insomnia	44.35	12.72	230	35121	360360	110193588
Gastrooesophageal reflux disease	43.93	12.72	142	35209	179834	110374114
Lower respiratory tract infection	43.36	12.72	12	35339	243094	110310854
Abnormal behaviour	42.09	12.72	57	35294	38982	110514966
Compulsions	42.05	12.72	12	35339	408	110553540
Binge eating	41.38	12.72	13	35338	617	110553331
Speech disorder	41.10	12.72	72	35279	61497	110492451
Orthostatic hypotension	41.06	12.72	75	35276	66174	110487774
Pyrexia	40.66	12.72	149	35202	898116	109655832
Off label use	39.77	12.72	299	35052	1499886	109054062
Drug intolerance	39.50	12.72	43	35308	406469	110147479
Illusion	39.36	12.72	17	35334	1990	110551958
Sleep attacks	39.16	12.72	10	35341	221	110553727
Asthma	39.01	12.72	171	35180	250120	110303828
Joint swelling	38.61	12.72	51	35300	442794	110111154
Parkinsonian gait	38.29	12.72	14	35337	1058	110552890
Hypersomnia	38.19	12.72	46	35305	28015	110525933
Urinary tract infection	37.30	12.72	204	35147	326078	110227870
Tension	36.98	12.72	22	35329	5056	110548892
Exposure during pregnancy	36.70	12.72	5	35346	167419	110386529
Agitation	35.96	12.72	98	35253	112953	110440995
Stomatitis	35.75	12.72	21	35330	270221	110283727
Disturbance in attention	35.69	12.72	68	35283	61927	110492021
Libido increased	35.53	12.72	17	35334	2522	110551426
Obsessive-compulsive disorder	34.45	12.72	24	35327	7217	110546731
Tardive dyskinesia	34.30	12.72	31	35320	13548	110540400
Psychotic symptom	34.16	12.72	19	35332	3848	110550100
Irritable bowel syndrome	33.51	12.72	6	35345	164209	110389739
Stoma site pain	33.24	12.72	15	35336	1948	110552000
Product dispensing error	33.06	12.72	33	35318	16312	110537636
Reduced facial expression	32.42	12.72	18	35333	3633	110550315
Akinesia	32.34	12.72	18	35333	3649	110550299
Logorrhoea	32.30	12.72	20	35331	4937	110549011
Dementia	32.27	12.72	45	35306	31628	110522320
Stoma site reaction	32.26	12.72	10	35341	454	110553494
Posture abnormal	31.72	12.72	19	35332	4419	110549529
Mania	31.47	12.72	36	35315	20760	110533188
Muscle injury	31.35	12.72	4	35347	140803	110413145
Multiple sclerosis relapse	31.29	12.72	57	35294	50183	110503765
Parkinsonism	31.23	12.72	37	35314	22150	110531798
Inflammation	30.14	12.72	12	35339	193226	110360722
Completed suicide	30.04	12.72	155	35196	242226	110311722
Energy increased	29.61	12.72	17	35334	3657	110550291
Oromandibular dystonia	29.52	12.72	12	35339	1207	110552741
Impaired healing	29.43	12.72	13	35338	196704	110357244
Device dislocation	29.30	12.72	43	35308	31661	110522287
Rapid eye movement sleep behaviour disorder	29.12	12.72	10	35341	629	110553319
Wound	28.56	12.72	20	35331	234417	110319531
Muscle spasms	28.54	12.72	169	35182	277988	110275960
Periodic limb movement disorder	28.25	12.72	9	35342	447	110553501
Dizziness	28.22	12.72	344	35007	697849	109856099
Blood cholesterol increased	27.97	12.72	12	35339	184773	110369175
Rheumatoid arthritis	27.67	12.72	33	35318	299580	110254368
Polyp	27.63	12.72	24	35327	9956	110543992
Hyperphagia	27.56	12.72	16	35335	3515	110550433
Confusional state	26.95	12.72	248	35103	468432	110085516
Middle insomnia	26.91	12.72	33	35318	20469	110533479
Memory impairment	26.56	12.72	129	35222	196815	110357133
Depression	26.51	12.72	183	35168	317152	110236796
Death	26.39	12.72	340	35011	698529	109855419
Hallucinations, mixed	26.30	12.72	22	35329	8671	110545277
Movement disorder	26.17	12.72	44	35307	36360	110517588
Bursitis	25.96	12.72	5	35346	129913	110424035
Liver disorder	25.39	12.72	7	35344	142236	110411712
Parkinsonian rest tremor	25.22	12.72	8	35343	392	110553556
Alopecia	25.18	12.72	49	35302	364704	110189244
Progressive supranuclear palsy	25.15	12.72	7	35344	217	110553731
Catecholamines urine increased	25.11	12.72	5	35346	33	110553915
Stoma site infection	25.06	12.72	12	35339	1783	110552165
Cognitive disorder	25.02	12.72	73	35278	87438	110466510
Somatic delusion	24.22	12.72	9	35342	712	110553236
Pleurothotonus	24.07	12.72	13	35338	2485	110551463
Transvestism	23.80	12.72	4	35347	8	110553940
Surgery	23.41	12.72	45	35306	41238	110512710
Compulsive sexual behaviour	23.29	12.72	7	35344	286	110553662
Dependence	22.99	12.72	13	35338	2716	110551232
Apathy	22.72	12.72	27	35324	16212	110537736
Device occlusion	22.50	12.72	26	35325	15159	110538789
Resting tremor	22.49	12.72	11	35340	1712	110552236
Ill-defined disorder	22.48	12.72	11	35340	156842	110397106
Psychomotor hyperactivity	22.46	12.72	30	35321	20247	110533701
Medical device site dryness	22.44	12.72	5	35346	60	110553888
Device connection issue	22.42	12.72	10	35341	1264	110552684
Psoriatic arthropathy	22.41	12.72	18	35333	196743	110357205
Incorrect product dosage form administered	22.33	12.72	7	35344	330	110553618
Hypokinesia	22.22	12.72	31	35320	21795	110532153
Arthropathy	22.21	12.72	36	35315	287486	110266462
Excessive sexual fantasies	22.18	12.72	4	35347	14	110553934
Anxiety	22.10	12.72	187	35164	344891	110209057
Gastrointestinal disorder	21.96	12.72	27	35324	241925	110312023
Parkinsonian crisis	21.76	12.72	4	35347	16	110553932
Joint range of motion decreased	21.74	12.72	6	35345	121826	110432122
Neuroleptic malignant syndrome	21.66	12.72	39	35312	34020	110519928
Therapeutic response unexpected	21.54	12.72	32	35319	23811	110530137
Hypomania	21.36	12.72	21	35330	10189	110543759
Device issue	21.27	12.72	39	35312	34496	110519452
Infusion site abscess	21.27	12.72	7	35344	386	110553562
Restlessness	21.21	12.72	52	35299	56207	110497741
Sexually inappropriate behaviour	21.17	12.72	8	35343	663	110553285
Occipital neuralgia	20.79	12.72	8	35343	696	110553252
Eczema eyelids	20.70	12.72	7	35344	420	110553528
Blood catecholamines increased	20.60	12.72	5	35346	89	110553859
Neutropenia	20.49	12.72	57	35294	374563	110179385
Poor quality sleep	20.27	12.72	34	35317	28043	110525905
Nocturia	20.15	12.72	26	35325	16964	110536984
Extra dose administered	20.03	12.72	22	35329	12137	110541811
Hyperhidrosis	19.98	12.72	115	35236	187183	110366765
Malignant neoplasm progression	19.84	12.72	16	35335	174551	110379397
Camptocormia	19.78	12.72	7	35344	481	110553467
Limbic encephalitis	19.72	12.72	8	35343	800	110553148
Hypertension	19.65	12.72	90	35261	509994	110043954
Persecutory delusion	19.20	12.72	16	35335	6275	110547673
Rash	19.18	12.72	169	35182	820795	109733153
Obsessive thoughts	19.05	12.72	9	35342	1298	110552650
Excessive masturbation	19.03	12.72	5	35346	124	110553824
Nonspecific reaction	19.01	12.72	12	35339	3062	110550886
Hepatitis	19.01	12.72	3	35348	90051	110463897
Stoma site odour	18.99	12.72	5	35346	125	110553823
Quality of life decreased	18.91	12.72	23	35328	14146	110539802
Paranoia	18.76	12.72	29	35322	22345	110531603
Mucosal inflammation	18.59	12.72	4	35347	96137	110457811
Discomfort	18.41	12.72	25	35326	214682	110339266
Stoma site hypergranulation	18.33	12.72	7	35344	597	110553351
Interstitial lung disease	18.17	12.72	11	35340	139323	110414625
Patient elopement	17.97	12.72	6	35345	346	110553602
Device kink	17.91	12.72	10	35341	2039	110551909
Urticaria	17.82	12.72	48	35303	318809	110235139
Stoma site inflammation	17.82	12.72	8	35343	1027	110552921
Hallucination, auditory	17.78	12.72	31	35320	26366	110527582
Cerebral atrophy	17.74	12.72	18	35333	9067	110544881
Homosexuality	17.73	12.72	4	35347	51	110553897
Therapeutic response shortened	17.71	12.72	33	35318	29550	110524398
Thrombocytopenia	17.69	12.72	55	35296	348830	110205118
Anticholinergic syndrome	17.64	12.72	13	35338	4267	110549681
Suspected suicide	17.62	12.72	23	35328	15176	110538772
Stoma site irritation	17.60	12.72	6	35345	369	110553579
Dermatitis contact	17.57	12.72	22	35329	13931	110540017
Dysstasia	17.54	12.72	35	35316	32951	110520997
Stoma site extravasation	17.43	12.72	6	35345	380	110553568
Rehabilitation therapy	17.42	12.72	10	35341	2151	110551797
Pancytopenia	17.38	12.72	25	35326	209588	110344360
Hypertonia	17.05	12.72	17	35334	8389	110545559
Injury	16.92	12.72	19	35332	177246	110376702
Exhibitionism	16.88	12.72	4	35347	64	110553884
Dysphagia	16.83	12.72	95	35256	153505	110400443
Wound infection	16.75	12.72	5	35346	96460	110457488
Suspiciousness	16.71	12.72	7	35344	760	110553188
Salivary gland cancer stage IV	16.66	12.72	4	35347	68	110553880
Wrong product administered	16.63	12.72	19	35332	10941	110543007
Loss of consciousness	16.26	12.72	113	35238	196193	110357755
Grip strength decreased	16.20	12.72	3	35348	80171	110473777
Wheezing	16.16	12.72	36	35315	255194	110298754
Blister	16.16	12.72	30	35321	227346	110326602
Musculoskeletal pain	16.01	12.72	21	35330	183002	110370946
Paraphilia	15.95	12.72	4	35347	82	110553866
Multiple organ dysfunction syndrome	15.91	12.72	15	35336	151695	110402253
Crying	15.86	12.72	29	35322	25599	110528349
Labelled drug-disease interaction issue	15.68	12.72	4	35347	88	110553860
Infusion site induration	15.65	12.72	8	35343	1368	110552580
Generalised onset non-motor seizure	15.64	12.72	4	35347	89	110553859
Limb injury	15.50	12.72	36	35315	37600	110516348
Theft	15.37	12.72	5	35346	266	110553682
Tic	15.28	12.72	11	35340	3482	110550466
Suicidal ideation	15.24	12.72	65	35286	93872	110460076
Neutrophil count increased	15.22	12.72	34	35317	34618	110519330
Neutrophil count decreased	15.15	12.72	10	35341	120931	110433017
Hypersensitivity	15.12	12.72	72	35279	403926	110150022
Thunderclap headache	15.07	12.72	6	35345	572	110553376
Coma scale abnormal	14.99	12.72	17	35334	9709	110544239
Vitamin B6 deficiency	14.89	12.72	6	35345	590	110553358
Pulmonary fibrosis	14.86	12.72	7	35344	102035	110451913
Secondary hypertension	14.82	12.72	6	35345	597	110553351
Teeth brittle	14.64	12.72	6	35345	616	110553332
Haemorrhoids	14.56	12.72	34	35317	35638	110518310
Cornea verticillata	14.55	12.72	5	35346	315	110553633
Product administration interrupted	14.53	12.72	18	35333	11274	110542674
Mental impairment	14.49	12.72	26	35325	22613	110531335
Micturition disorder	14.44	12.72	12	35339	4686	110549262
Mood altered	14.27	12.72	25	35326	21350	110532598
Renal impairment	14.17	12.72	24	35327	188421	110365527
Obsessive-compulsive personality disorder	14.10	12.72	4	35347	133	110553815
Lactic acidosis	14.09	12.72	6	35345	92805	110461143
Initial insomnia	14.08	12.72	17	35334	10372	110543576
Postural reflex impairment	14.05	12.72	3	35348	29	110553919
Vomiting	13.97	12.72	206	35145	910469	109643479
Disorientation	13.96	12.72	52	35299	70619	110483329
Salivary hypersecretion	13.80	12.72	22	35329	17399	110536549
Female orgasmic disorder	13.79	12.72	3	35348	32	110553916
Unevaluable event	13.78	12.72	46	35305	59181	110494767
Nasal congestion	13.69	12.72	65	35286	98217	110455731
Nightmare	13.68	12.72	35	35316	38828	110515120
Syncope	13.61	12.72	111	35240	202425	110351523
Arthralgia	13.52	12.72	172	35179	779460	109774488
Toxicity to various agents	13.50	12.72	94	35257	480461	110073487
Lung disorder	13.48	12.72	23	35328	180024	110373924
Increased appetite	13.39	12.72	20	35331	14957	110538991
Obesity	13.37	12.72	10	35341	113341	110440607
Abdominal discomfort	13.15	12.72	73	35278	393785	110160163
Leukopenia	13.09	12.72	17	35334	148774	110405174
Drug reaction with eosinophilia and systemic symptoms	12.96	12.72	5	35346	82090	110471858
Therapeutic product effect delayed	12.86	12.72	11	35340	4468	110549480

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04BC04	NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopamine agonists
FDA MoA	N0000000117	Dopamine Agonists
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018491	Dopamine Agonists
MeSH PA	D018726	Anti-Dyskinesia Agents
FDA EPC	N0000175768	Nonergot Dopamine Agonist
CHEBI has role	CHEBI:35470	central nervous system drug
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:51065	dopamine agonist
CHEBI has role	CHEBI:66956	antidyskinesia agent

Related Drugs by ATC class:

N04BC Dopamine agonists 8 drugs

apomorphinebromocriptinecabergolinedihydroergocryptinepergolidepiribedilpramipexolerotigotine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Restless legs	indication	32914008	DOID:0050425
Parkinson's disease	indication	49049000	DOID:14330
Hallucinations	contraindication	7011001
Dyskinesia	contraindication	9748009
Orthostatic hypotension	contraindication	28651003
Low blood pressure	contraindication	45007003
Bradycardia	contraindication	48867003
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Psychotic disorder	contraindication	69322001
Syncope	contraindication	271594007
Drowsy	contraindication	271782001
Central nervous system depression	contraindication	418072004
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

Product	Applicant	Ingredients
CLEVOR	Orion Corp.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.82	acidic
pKa2	9.18	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	8.14		IUPHAR	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.73		PDSP
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.54		WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		EC50	6.85		CHEMBL
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.42		PDSP
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	5.82		PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.12		WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	7.43		WOMBAT-PK
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	4.38		CHEMBL
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.86		PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	5.92		PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	6.07		WOMBAT-PK
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	4.49		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	5.57		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		IC50	5.17		CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	7.53		CHEMBL

External reference:

ID	Source
4024081	VUID
N0000022086	NUI
D00784	KEGG_DRUG
91374-20-8	SECONDARY_CAS_RN
4021058	VANDF
4024081	VANDF
C0244821	UMLSCUI
CHEBI:8888	CHEBI
CHEMBL589	ChEMBL_ID
CHEMBL1200411	ChEMBL_ID
DB00268	DRUGBANK_ID
C046649	MESH_SUPPLEMENTAL_RECORD_UI
5095	PUBCHEM_CID
7295	IUPHAR_LIGAND_ID
6436	INN_ID
030PYR8953	UNII
152951	RXNORM
11369	MMSL
136707	MMSL
25995	MMSL
5434	MMSL
d04215	MMSL
006273	NDDF
006274	NDDF
108473005	SNOMEDCT_US
108474004	SNOMEDCT_US
372499000	SNOMEDCT_US
030PYR8953	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	0228-3640	TABLET, FILM COATED, EXTENDED RELEASE	6 mg	ORAL	ANDA	18 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	0228-3658	TABLET, FILM COATED, EXTENDED RELEASE	2 mg	ORAL	ANDA	18 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	0228-3659	TABLET, FILM COATED, EXTENDED RELEASE	4 mg	ORAL	ANDA	18 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	0228-3660	TABLET, FILM COATED, EXTENDED RELEASE	8 mg	ORAL	ANDA	18 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	0228-3661	TABLET, FILM COATED, EXTENDED RELEASE	12 mg	ORAL	ANDA	18 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8188	TABLET, FILM COATED	0.25 mg	ORAL	ANDA	27 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8189	TABLET, FILM COATED	0.50 mg	ORAL	ANDA	27 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8190	TABLET, FILM COATED	1 mg	ORAL	ANDA	27 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8191	TABLET, FILM COATED	2 mg	ORAL	ANDA	27 sections
ROPINIROLE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6373	TABLET, FILM COATED	0.25 mg	ORAL	ANDA	27 sections
ROPINIROLE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6374	TABLET, FILM COATED	1 mg	ORAL	ANDA	27 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	10135-673	TABLET, FILM COATED	0.25 mg	ORAL	ANDA	28 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	10135-674	TABLET, FILM COATED	0.50 mg	ORAL	ANDA	28 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	10135-675	TABLET, FILM COATED	1 mg	ORAL	ANDA	28 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	10135-676	TABLET, FILM COATED	2 mg	ORAL	ANDA	28 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	10135-677	TABLET, FILM COATED	3 mg	ORAL	ANDA	28 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	10135-678	TABLET, FILM COATED	4 mg	ORAL	ANDA	28 sections
Ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	10135-679	TABLET, FILM COATED	5 mg	ORAL	ANDA	28 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-643	TABLET	1 mg	ORAL	ANDA	14 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-734	TABLET	2 mg	ORAL	ANDA	14 sections
ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-232	TABLET, FILM COATED	0.25 mg	ORAL	ANDA	27 sections
ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-233	TABLET, FILM COATED	0.50 mg	ORAL	ANDA	27 sections
ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-234	TABLET, FILM COATED	1 mg	ORAL	ANDA	27 sections
ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-235	TABLET, FILM COATED	2 mg	ORAL	ANDA	27 sections
ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-236	TABLET, FILM COATED	3 mg	ORAL	ANDA	27 sections
ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-237	TABLET, FILM COATED	4 mg	ORAL	ANDA	27 sections
ropinirole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-238	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-792	TABLET, COATED	0.25 mg	ORAL	ANDA	22 sections
ropinirole hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-793	TABLET, FILM COATED	0.50 mg	ORAL	ANDA	12 sections
ROPINIROLE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-794	TABLET, COATED	1 mg	ORAL	ANDA	22 sections